Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
ImmunityBio, Inc.
ImmunityBio, Inc.
M.D. Anderson Cancer Center
ImmunityBio, Inc.
AstraZeneca
The Lymphoma Academic Research Organisation
Northwestern University
Indiana University
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
Massachusetts General Hospital
Eli Lilly and Company
University of Washington
M.D. Anderson Cancer Center
Northwestern University
Brown University
University of Rochester
Washington University School of Medicine
University of Utah
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Celgene
Fred Hutchinson Cancer Center
University of Washington
Regeneron Pharmaceuticals
City of Hope Medical Center
Hospices Civils de Lyon
Mayo Clinic
Shanghai Junshi Bioscience Co., Ltd.
Wake Forest University Health Sciences
Takeda
Chinese PLA General Hospital
Roswell Park Cancer Institute
University of Chicago
CARGO Therapeutics
Columbia University
Miltenyi Biomedicine GmbH